Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthBCBS South Carolina psychiatric step therapy Prior…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Formulary step therapy and prior authorization criteria for selected psychiatric and related drugs

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs step therapy and trial-of-therapy criteria for specific outpatient prescription products (primarily psychiatric medications and related agents) under the South Carolina PDP Basic plan; it affects prescribers and pharmacy benefit adjudication for plan members in South Carolina.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization criteria for selected psychiatric and related drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument trials of required alternative agents (e.g., two generic antidepressants for designated products or specified agent trials for products like Invega Hafyera, Zonisade, Relistor, and Diclofenac GEL) when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≈12listed products or product groups with criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    new-starts limitations
    1topical-agent requirement
    1antidepressant multi-generic trials

    Coverage Criteria and Product-Specific Requirements

    Product-specific step therapy requirements

    Covered when the following product-specific trial requirements are met (and continuation of prior therapy is approved):

    Diclofenac GEL 3%: Trial of either topical fluorouracil or topical imiquimod is required.

    From chunk 2

    Exxua / related antidepressant products: Trial of two generics from the listed formulary antidepressant agents (bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine HCl) is required; approve continuation of prior therapy.

    From chunk 4

    Fanapt and related atypical antipsychotics: Trial of two oral generic formulary atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) is required; approve continuation of prior therapy.

    From chunk 6

    Invega Hafyera: Trial of Invega Sustenna or Invega Trinza is required for new starts; approve continuation of prior therapy.

    From chunk 8

    Relistor: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose is required.

    From chunk 10

    Zonisade: Trial of generic zonisamide capsule is required for new starts; approve continuation of prior therapy.

    From chunk 12

    Continuation of prior therapy is permitted for many listed products when documentation of prior therapy is provided. For new starts, specific step therapy requirements apply to selected products: for antidepressant products (Exxua, Fetzima and their titration packs) a trial of two generic formulary antidepressants is required from the following list: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine HCl; approval is granted for continuation of prior therapy. For atypical antipsychotics (Fanapt and related products) a trial of two oral generic formulary atypical antipsychotics is required (choose from asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone); continuation of prior therapy is approved. For Invega Hafyera new starts, a trial of Invega Sustenna or Invega Trinza is required; continuation of prior therapy is approved. For Zonisade new starts, a trial of a generic zonisamide capsule is required; continuation of prior therapy is approved.

    Provider Actions, Documentation, and Denial Risks

    Prior Authorization

    Antidepressant prior authorization — trial of two generics

    Prior authorization for certain branded antidepressant products (Exxua, Fetzima and related titration packs) requires documentation of trials of two generic formulary antidepressant agents from the enumerated list; continuation of prior therapy is approved without repeating steps.

    • Required trial agents (generics): bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl
    Prior Authorization

    Atypical antipsychotic prior authorization — two oral generics required

    Prior authorization for Fanapt, Lybalvi, Secuado and related atypical antipsychotic products requires documentation of trials of two oral generic formulary atypical antipsychotics; continuation of prior therapy is approved.

    • Required trial agents (generics): asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone

    Pharmacotherapy Modalities

    Antidepressant pharmacotherapy

    Antidepressant step: Trial of two generic formulary antidepressants from the enumerated list (bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride) is required for Exxua and related products. Approve continuation of prior therapy.

    From chunk 4

    Antipsychotic pharmacotherapy

    Atypical antipsychotic step: Trial of two oral generic formulary atypical antipsychotics (asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone) is required for Fanapt and related products. Approve continuation of prior therapy.

    From chunk 6

    Definitions and Key Terms

    Titration Pack — definition entry
    TermTitration Pack
    DefinitionA medication packaging or regimen used to initiate therapy with stepwise dose adjustments (referred to in the policy as 'Titration Pack').
    Examples in policyFanapt Titration Pack C; Exxua Titration Pack; Fetzima Titration Pack (policy references titration packs alongside specific products).

    Background and Scope

    This policy establishes formulary step requirements and prior authorization expectations for selected outpatient prescription products within the South Carolina PDP Basic plan. It is intended to guide pharmacy benefit adjudication and prescriber documentation by listing required alternative-agent trials for nonpreferred or brand products and by noting that documentation of prior therapy generally permits continuation without repeating step requirements. Where noted, step requirements apply to new starts only and continuation of previously established therapy is approved when prior treatment is documented.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization criteria for selected psychiatric and related drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument trials of required alternative agents (e.g., two generic antidepressants for designated products or specified agent trials for products like Invega Hafyera, Zonisade, Relistor, and Diclofenac GEL) when requesting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria and Product-Specific RequirementsProvider Actions, Documentation, and Denial RisksPharmacotherapy ModalitiesDefinitions and Key TermsBackground and Scope
    Prior Authorization

    Invega Hafyera prior authorization — trial of Sustenna or Trinza

    New starts of Invega Hafyera require prior trial of either Invega Sustenna or Invega Trinza for approval; continuation of prior therapy is approved when documented.

    • Required trial for new starts: Invega Sustenna or Invega Trinza
    Prior Authorization

    Zonisade prior authorization — trial of generic zonisamide

    New starts of Zonisade require trial of a generic zonisamide capsule prior to approval; continuation of prior therapy is approved when documented.

    • Required trial for new starts: generic zonisamide capsule
    Prior Authorization

    Relistor prior authorization — trial of specified laxatives required

    Prior authorization for Relistor requires documentation of a trial of specified constipation agents (laxatives) before approval.

    • Required trial agents: lubiprostone; Constulose; Enulose; Generlac; lactulose
    Prior Authorization

    Diclofenac GEL prior authorization — topical agent trial required

    Prior authorization for Diclofenac Sodium GEL 3% (actinic keratosis) requires documentation of trial of either topical fluorouracil or topical imiquimod before approval.

    • Required trial agents: topical fluorouracil or topical imiquimod
    Step Therapy

    Antidepressant step therapy — two generic trials required

    Step therapy for Exxua and related antidepressant products requires documented trials of two generic formulary antidepressants from the enumerated list; continuation of prior therapy is approved.

    • Acceptable trial agents include: bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl
    Step Therapy

    Atypical antipsychotic step therapy — two oral generic trials required

    Step therapy for Fanapt and related atypical antipsychotics requires documented trials of two oral generic formulary atypical antipsychotics; continuation of prior therapy is approved.

    • Acceptable trial agents: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
    Step Therapy

    Invega Hafyera step therapy — Sustenna or Trinza required for new starts

    Step therapy for new starts of Invega Hafyera requires trial of Invega Sustenna or Invega Trinza; continuation of prior therapy is approved.

    • Required trial for new starts: Invega Sustenna or Invega Trinza
    Step Therapy

    Zonisade step therapy — generic zonisamide required for new starts

    Step therapy for new starts of Zonisade requires trial of a generic zonisamide capsule; continuation of prior therapy is approved.

    • Required trial for new starts: generic zonisamide capsule
    Step Therapy

    Relistor step therapy — trial of listed laxatives required

    Step therapy for Relistor requires prior trial of one of the listed constipation agents before approval.

    • Required trial agents: lubiprostone; Constulose; Enulose; Generlac; lactulose
    Step Therapy

    Diclofenac GEL step therapy — topical fluorouracil or imiquimod required

    Step therapy for Diclofenac Sodium GEL 3% (actinic keratosis) requires trial of topical fluorouracil or topical imiquimod prior to approval.

    • Required trial agents: topical fluorouracil or topical imiquimod
    Documentation Required

    Antidepressant documentation — record two generic trials or prior therapy

    Document trials of two generic formulary antidepressant agents from the enumerated list for new-start approvals, or provide evidence of prior therapy for continuation approvals.

    • Document the specific agents tried and dates of trial
    • Continuation: provide evidence of member's prior therapy to avoid repeating steps
    Documentation Required

    Atypical antipsychotic documentation — record two oral generic trials or prior therapy

    Document trials of two oral generic formulary atypical antipsychotic agents from the enumerated list for new-start approvals, or provide evidence of prior therapy for continuation approvals.

    • Document the specific agents tried and dates of trial
    • Continuation: provide evidence of member's prior therapy to avoid repeating steps
    Documentation Required

    Invega Hafyera documentation — trial of Sustenna or Trinza required for new starts

    For Invega Hafyera new starts, document trial of Invega Sustenna or Invega Trinza; for continuation requests, provide evidence of prior therapy.

    • Document which paliperidone LAI was used (Sustenna or Trinza) and trial dates
    • Continuation: include prior therapy records
    Documentation Required

    Relistor documentation — record prior laxative trials

    Document a trial of a listed constipation agent(s) (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before pursuing Relistor approval.

    • Document agent(s) tried and duration of therapy
    Documentation Required

    Zonisade documentation — record generic zonisamide trial or prior therapy

    Document trial of a generic zonisamide capsule for Zonisade new starts; for continuation requests, provide evidence of prior therapy.

    • Document the generic zonisamide product and dates of trial
    • Continuation: include prior therapy records
    Documentation Required

    Diclofenac GEL documentation — record topical agent trial

    Document trial of topical fluorouracil or topical imiquimod for actinic keratosis-related Diclofenac GEL 3% requests before approval.

    • Document which topical agent was used and treatment dates
    Denial Risk

    Antidepressant denial risk — missing generic trials may trigger denial

    Failure to document trials of two generic formulary antidepressants from the enumerated list may result in denial of approval for Exxua, Fetzima and related products; continuation of prior therapy is approved when documented.

    • Ensure records show two distinct generic antidepressant trials or provide prior therapy evidence to avoid denial
    Denial Risk

    Atypical antipsychotic denial risk — missing generic trials may trigger denial

    Failure to document trials of two oral generic formulary atypical antipsychotics may result in denial for Fanapt and related products; continuation of prior therapy is approved when documented.

    • Provide documentation of two distinct generic atypical antipsychotic trials to avoid denial
    Denial Risk

    Invega Hafyera denial risk — missing Sustenna/Trinza trial may trigger denial

    Failure to document trial of Invega Sustenna or Invega Trinza for new-start Invega Hafyera requests may result in denial; continuation of prior therapy is approved when documented.

    • For new starts, include trial documentation of Sustenna or Trinza to avoid denial
    Denial Risk

    Relistor denial risk — missing laxative trials may trigger denial

    Failure to document trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose may result in denial for Relistor.

    • Document prior laxative therapy to support Relistor approval
    Denial Risk

    Zonisade denial risk — missing generic zonisamide trial may trigger denial

    Failure to trial a generic zonisamide capsule for Zonisade new starts may result in denial; continuation of prior therapy is approved when documented.

    • For new starts, document generic zonisamide trial to avoid denial
    Denial Risk

    Diclofenac GEL denial risk — missing topical trial may trigger denial

    Failure to document trial of topical fluorouracil or topical imiquimod may result in denial for Diclofenac Sodium GEL 3% (actinic keratosis).

    • Document prior topical therapy to support Diclofenac GEL approval